Billiau Alfons
Rega Institute, University of Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium.
J Clin Virol. 2007 Aug;39(4):241-65. doi: 10.1016/j.jcv.2007.04.023. Epub 2007 Jun 18.
This article analyzes the conceptual and technological context in which, over a period of 50 years, exploration of the biological and clinical significance of type I interferon has evolved. The elaboration of techniques for production and purification of mouse and human interferons and the establishment of laboratory-size production units have been of crucial importance in this process. Animal experiments have been invaluable for elucidation of mechanisms underlying the in vivo antiviral, anti-tumour and immunomodulatory potential of interferon, but have been of limited help to define the areas of clinical applicability. Proof of principle for applications as they are established today has come from clinical trials performed quite independently of evidence from animal experiments.
本文分析了在50年的时间里,对I型干扰素的生物学和临床意义的探索得以发展的概念和技术背景。小鼠和人干扰素生产及纯化技术的完善以及实验室规模生产单位的建立在这一过程中至关重要。动物实验对于阐明干扰素在体内的抗病毒、抗肿瘤和免疫调节潜力的机制非常宝贵,但在确定临床适用范围方面帮助有限。如今已确立的应用原理证明来自于与动物实验证据完全独立进行的临床试验。